Yonhap Infomax NewsJan 30
Celltrion Group stands out as the only major pharma-bio chaebol to boost market cap under President Lee, driven by strong earnings, U.S. expansion, and realistic guidance.
#YonhapInfomax #CelltrionGroup #MarketCapitalization #Pharmaceuticals #EarningsGuidance #USExpansion #Economics #FinancialMarkets #Banking #Securities #Bonds #StockMarket
https://en.infomaxai.com/news/articleView.html?idxno=102954
Celltrion Group Adds 14 Trillion Won in Market Cap Under Lee Administration—Only Pharma-Bio Player Among Top 30 Chaebol

Celltrion Group stands out as the only major pharma-bio chaebol to boost market cap under President Lee, driven by strong earnings, U.S. expansion, and realistic guidance.

Yonhap Infomax
Yonhap Infomax NewsSep 18, 2025
Celltrion Group’s aggressive share buybacks and cancellations have failed to lift its stock, with analysts stressing that improving return on equity (ROE) is essential amid persistent sector uncertainties and rising securities lending balances.
#YonhapInfomax #CelltrionGroup #ShareBuyback #ROE #KOSPI200 #SecuritiesLending #Economics #FinancialMarkets #Banking #Securities #Bonds #StockMarket
https://en.infomaxai.com/news/articleView.html?idxno=82286
What Celltrion Group—A Rare Champion of Shareholder Returns in Korea—Still Needs

Celltrion Group’s aggressive share buybacks and cancellations have failed to lift its stock, with analysts stressing that improving return on equity (ROE) is essential amid persistent sector uncertainties and rising securities lending balances.

Yonhap Infomax